Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CTSH
65 Stocks Moving In Thursday's Mid-Day Session
32 Stocks Moving In Thursday's Pre-Market Session
Related ATRA
Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
45 Biggest Movers From Yesterday
Bulletproof Investing Performance Update: Week 38 (Seeking Alpha)

 

  • Goldman Sachs downgraded Cognizant Technology Solutions Corp (NASDAQ: CTSH) from Buy to Neutral. The price target for Cognizant Technology has been lowered from $68 to $61. Cognizant Technology shares fell 1.35 percent to $53.30 in pre-market trading.
  • Analysts at Stifel Nicolaus downgraded AMC Networks Inc (NASDAQ: AMCX) from Buy to Hold. AMC Networks shares fell 1.10 percent to $51.40 in pre-market trading.
  • Gabelli & Co. downgraded Penske Automotive Group, Inc. (NYSE: PAG) from Buy to Hold. Penske Automotive shares rose 0.53 percent to close at $49.40 on Wednesday.
  • Analysts at Bank of America downgraded VF Corp (NYSE: VFC) from Buy to Underperform. VF Corp shares dropped 3.08 percent to $56.25 in pre-market trading.
  • CLSA downgraded Monsanto Company (NYSE: MON) from Buy to Underperform. Monsanto shares dropped 0.08 percent to $106.67 in pre-market trading.
  • Analysts at Credit Suisse downgraded Apigee Corp (NASDAQ: APIC) from Outperform to Neutral. Apigee shares gained 0.03 percent to close at $17.45 on Wednesday.
  • Analysts at BMO Capital downgraded Vitae Pharmaceuticals Inc (NASDAQ: VTAE) from Outperform to Market Perform. Vitae Pharmaceuticals shares declined 0.24 percent to $20.80 in pre-market trading.
  • Goldman Sachs downgraded Atara Biotherapeutics Inc (NASDAQ: ATRA) from Neutral to Sell. The price target for Atara Biotherapeutics has been lowered from $23 to $16. Atara Biotherapeutics shares rose 1.81 percent to close at $21.33 on Wednesday.
  • Barclays downgraded Arch Capital Group Ltd. (NASDAQ: ACGL) from Overweight to Equal-weight. Arch Capital shares fell 0.53 percent to $80.22 in pre-market trading.

Latest Ratings for CTSH

DateFirmActionFromTo
Aug 2018JP MorganDowngradesOverweightNeutral
Aug 2018KeyBancMaintainsOverweightOverweight
May 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for CTSH
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (ACGL + AMCX)

View Comments and Join the Discussion!

FDA Votes In Favor Of Removing Side-Effect Warning On Pfizer's Chantix

EUR/USD Erases Gains